Tag
GLP-1
Page 1 of 4
Semaglutide and tirzepatide tracked half the femoral fractures of another diabetes drug
The worry about weight-loss drugs is that fast loss costs muscle and bone, which should show up as broken hips. Comparing 27,896 matched over-65s against a rival diabetes medicine, fractures and falls both ran lower over a year.
Sep 1, 2026
Sudden vision loss hit 3 more GLP-1 users per 10,000 over 18 months than two rival diabetes drugs
An Annals of Internal Medicine target trial emulation compared GLP-1 users against two other diabetes drug classes. Ischemic optic neuropathy was more common on GLP-1s, concentrated in men, over-50s and those with eye or heart disease.
Aug 28, 2026
Semaglutide kept cutting calories after hunger relief faded
A 60-week trial in 120 adults measured what people actually ate. Those on semaglutide still ate around 270 fewer calories at week 60, even though the appetite benefits they reported had gone.
Aug 6, 2026
An oral GLP-1 pill cut weight 9% in a phase 2 trial
A trial in Nature Communications tested a once-daily GLP-1 tablet in 235 Chinese adults with obesity. The top dose beat placebo by about 7 percentage points over 26 weeks, with the usual gut side effects.
Aug 4, 2026